Skip to content

Rebound Exercise in Neurological Disorders

Use of Rebound Exercise in Community-dwelling Individuals With Neurological Disorders

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05526508
Enrollment
52
Registered
2022-09-02
Start date
2022-12-12
Completion date
2023-07-31
Last updated
2023-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurological Diseases or Conditions

Keywords

neurological disorders, rebound, mini-trampoline, exercise /therapy, walking speed, fall risk, quality of life

Brief summary

This study will be a pretest-posttest interventional trial investigating the use of rebound exercise in community-dwelling individuals with neurological disorders.

Detailed description

Neurological disorders are linked to various problems, including but not limited to movement impairments, balance, fear of falls, reduced exercise tolerance, loss of muscle strength, reduced functional independence, sedentary behaviour and reduced quality of life. These impairments can lead to physical deconditioning, functional dependency and extreme disability if left unmanaged, creating the need for prompt treatment. Rebound exercise is an effective and safe form of aerobic exercise that has been successfully used in some populations. It can be included in rehabilitating people with neurological disorders for its beneficial effects on humans and minimal stress on the heart and joints. Its fun-giving experience makes it easier to engage regularly compared to traditional exercise tools that may feel like a task. It is also more affordable and less time-consuming than other standard modalities. The few available studies on rebound exercise in neurological disorders were mostly in inpatients, and evidence is scarce on the use of rebound exercise in community-dwelling individuals with neurological disorders. It is thus necessary to investigate its use in the community context as well as the minimal effective dosage of the intervention. This study will investigate the frequency of rebound exercise necessary to effect changes in physiological and functional outcomes such as heart rate, blood pressure, physical activity level, walking speed, risk of falls, cognitive function and quality of life. The enrolled participants will undergo 12 weeks of rebound exercise training once or twice weekly, depending on their frequency choice. Ethical approval has been sought and obtained from the Research Ethics Committee of Buckinghamshire New University. Eligible volunteer participants will be asked to sign the informed consent after the study has been explained to them. They will be assured of data confidentiality by anonymising their information and will also be informed of their right to withdraw at any point.

Interventions

Exercise training on the rebounder/ mini-trampoline with stability handles attached

Sponsors

Buckinghamshire New University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Only the outcome assessor will be blinded to the participant's frequency group

Intervention model description

There will be two frequency groups, once-weekly and twice-weekly, but the group's choice depends on the participants.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of a neurological disorder of upper motor neurone origin such as stroke, multiple sclerosis, Parkinson's disease, traumatic brain injury etc * must score 3 or less on the Modified Rankin Scale for disability status * must be able to walk with or without walking aids for at least 2 minutes * have a body weight of \<120 kg * must be able to understand therapy instructions.

Exclusion criteria

* Pregnancy * Other significant comorbidities * cardiovascular or respiratory system disorders * musculoskeletal disorders * visual or auditory sensory disorders. * cancer * genu recurvatum

Design outcomes

Primary

MeasureTime frameDescription
Change in baseline quality of life assessed by World Health Organisation Quality of Life Brief version (WHOQOLBREF) at 12 weeksBaseline and12 weeksWHOQOLBREF is a 12-item questionnaire assessing physical and psychological domains of quality of life. The scale has been validated among stroke patients of different ethnic groups (Kerber et al., 2013; Post et al., 2011). It is rated on a 5-point Likert scale ranging from 1-5, with higher scores indicating better quality of life. A significant advantage it has over the more extended version is its reduced administration time (5 minutes), making it a more practical tool in research and clinical practice.
Change in baseline risk of fall assessed by 3-Metre Backward Walk test at 12 weeksBaseline and12 weeks3-metre backward walk test (3MBWT) is valid, reliable and clinically suitable to detect little changes in motor functions related to proprioception in patients with neurological diseases (Kocaman et al., 2021). Of all battery tests assessed for fall risks in patients with Parkinson's disease (Carter et al., 2020), 3MBWT had the highest overall accuracy for retrospective falls. Backward walking measures are more sensitive to identify age-related changes in mobility than forward walking. From a marked point, the patient is asked to walk backwards as fast and safely as possible to a 3-metre marked end. They are free to look back if they wish. A time of 3 seconds or less indicates good balance and low fall risk, while a time of 4.5 seconds or more indicates a high fall risk.
Change in baseline walking speed assessed by 10-Metre Walk test (10MWT) at 12 weeksBaseline and 12 weeks10MWT has been shown to have excellent construct validity and reliability for patients with neurological diseases (Cheng et al., 2020). The individual is instructed to walk a set distance of 10 meters, and the time taken to walk the distance is noted. Assistive devices may be used but must be documented from test to test. Walking distance is measured in meters per second.
Change in baseline blood pressure and heart rate assessed by digital blood pressure monitor at 12 weeksBaseline and 12 weeksA digital Blood pressure monitor uses an inflatable air-bladder cuff, a battery-powered air pump and a pressure sensor for sensing arterial wall vibrations to measure blood pressure in an artery.
Change in baseline physical activity level assessed by International Physical Activity Questionnaire at 12 weeksBaseline and 12 weeksThe IPAQ is a 27-item self-reported measure of physical activity for use with individual adult patients. The IPAQ can be used clinically and in population research that compares physical activity levels between populations internationally.
Change in baseline cognitive function assessed by mini-cog at 12 weeksBaseline and 12 weeksThe Mini-Cog is a simple screening test for cognitive impairment. It combines a brief memory test and a scored clock-drawing test. It allows rapid screening for short-term memory defects, learning and different cognitive abilities impaired in dementia patients.

Secondary

MeasureTime frameDescription
Change in baseline grip strength assessed with a digital handheld dynamometer at 12 weeksBaseline and 12 weeksA Hand-Held Dynamometer is a valid and reliable assessment tool used for objectively quantifying muscle strength

Countries

United Kingdom

Contacts

Primary ContactAdaora J Okemuo, M.Sc
Adaora.Okemuo@bucks.ac.uk07883733407

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026